Categories: CancerNews

Profound Medical to Release Third Quarter 2022 Financial Results on November 3 – Conference Call to Follow

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

TORONTO, Oct. 13, 2022 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its third quarter 2022 financial results after market close on Thursday, November 3, 2022.

Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period.

Third Quarter 2022 Results Conference Call Details:
   
Date: Thursday, November 3, 2022
   
Time: 4:30 p.m. ET
   
Live Call Registration: https://register.vevent.com/register/BI9fe61ff681a946ce83ad793a7ce94310

The call will also be broadcast live and archived on the Company’s website at www.profoundmedical.com under “Webcasts” in the Investors section.

About Profound Medical Corp.

Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO® is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient’s natural functional abilities. TULSA-PRO® has the potential to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer, and the transition zone in large volume benign prostatic hyperplasia (“BPH”). TULSA-PRO® is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).

Profound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve® has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. The Company is in the early stages of exploring additional potential treatment markets for Sonalleve® where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.

For further information, please contact:

Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849

Staff

Recent Posts

FendX Announces Share Issuance Pursuant to IP License Agreement

Oakville, Ontario--(Newsfile Corp. - May 5, 2025) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF)…

28 minutes ago

The Lens Magazine Features Joe Kiani, Willow Laboratories Founder and Nutu Visionary, on Cover of Latest Issue Following LSI USA ‘25 Keynote

DANA POINT, Calif.--(BUSINESS WIRE)--The Lens, LSI’s executive-focused medtech magazine, proudly unveils Volume 2, Edition 3,…

2 hours ago

eMed Announces Collaboration with Aon to Provide a Digital GLP-1 Benefit Program for Aon colleagues

Partnership provides virtual clinical support with data driven measurement to improve adherence for obesity management MIAMI, May 5, 2025 /PRNewswire/ -- eMed®,…

2 hours ago

First Partner Jennifer Siebel Newsom Unveils Tech/Life Balance Guide in Conversation with Jonathan Haidt at Milken Institute Global Conference

In a featured conversation with social psychologist and author Jonathan Haidt, First Partner Jennifer Siebel…

2 hours ago

Abu Dhabi’s economic delegation to Japan explores new avenues to strengthen partnerships

ABU DHABI, UAE, May 5, 2025 /PRNewswire/ -- As part of Abu Dhabi's ongoing efforts…

2 hours ago